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Background: The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the combination of UMEC with
the long-acting β2-agonist (LABA) vilanterol (UMEC/VI) are approved maintenance treatments for chronic obstructive
pulmonary disease (COPD) in the US and EU. They are not indicated for the treatment of asthma.
Methods: In this 52-week, double-blind, placebo-controlled, parallel-group safety study (GSK study DB2113359;
NCT01316887), patients were randomized 2:2:1 to UMEC/VI 125/25 mcg, UMEC 125 mcg, or placebo. Study endpoints
included adverse events (AEs), clinical chemistry and hematology parameters, vital signs, 12-lead, and 24-hour Holter
electrocardiograms. COPD exacerbations and rescue medication use were assessed as safety parameters; lung function
was also evaluated.
Results: The incidence of on-treatment AEs, serious AEs (SAEs), and drug-related AEs was similar between treatment
groups (AEs: 52–58%; SAEs: 6–7%; drug-related AEs: 12–13%). Headache was the most common AE in each treatment
group (8–11%). AEs associated with the LAMA and LABA pharmacologic classes occurred at a low incidence across
treatment groups. No clinically meaningful effects on vital signs or laboratory assessments were reported for active
treatments versus placebo. The incidences of atrial arrhythmias with UMEC/VI 125/25 mcg were similar to placebo; for
UMEC 125 mcg, the incidences of ectopic supraventricular beats, sustained supraventricular tachycardia, and ectopic
supraventricular rhythm were ≥2% greater than placebo. With active treatments, COPD exacerbations were fewer
(13–15% of patients reporting ≥1 exacerbation) and on average less rescue medication was required (1.6–2.2 puffs/day)
versus placebo (24% reporting ≥1 exacerbation, 2.6 puffs/day). Both active treatments improved lung function versus
placebo.
Conclusion: UMEC/VI 125/25 mcg and UMEC 125 mcg were well tolerated over 12 months in patients with COPD.
Keywords: Bronchodilator, Long-acting muscarinic antagonist, Long-acting β2-adrenergic agonist, Combination* Correspondence: james_donohue@med.unc.edu
1Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
Full list of author information is available at the end of the article
© 2014 Donohue et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Donohue et al. Respiratory Research 2014, 15:78 Page 2 of 10
http://respiratory-research.com/content/15/1/78Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable condition characterized by persist-
ent airflow obstruction that is not fully reversible [1]. The
pharmacological management of stable COPD primarily
aims to improve symptoms and quality of life, optimize
lung function, reduce COPD exacerbations, and improve
exercise tolerance [1,2]. Bronchodilators are central to the
pharmacological management of COPD, and include long-
acting muscarinic antagonists (LAMAs) and long-acting
β2-adrenergic agonists (LABAs). Muscarinic antagonists
bind to M3 receptors, thereby blocking the bronchocon-
strictive response to cholinergic nervous stimulation [3],
while β2-agonists stimulate β2-adrenergic receptors and
increase levels of cyclic adenosine monophosphate
[2]. Both mechanisms facilitate airway smooth muscle
relaxation.
The combination of these distinct and complementary
mechanisms of action may provide the opportunity for im-
proved treatment efficacy. Indeed, the co-administration of
LAMAs and LABAs has been shown to produce signifi-
cantly greater improvements in lung function compared
with the monotherapy components in patients with COPD,
as have their short-acting counterparts [4-7]. In addition to
stabilizing lung function over 24 hours, the development of
a LAMA/LABA combination treatment may also improve
treatment adherence due to the convenience of a once-
daily treatment regimen [8], and administration of both
drugs via a single inhaler. A LAMA/LABA therapy may
also be associated with a lower risk of side effects in com-
parison with increasing the dose of a single agent [2].
The LAMA umeclidinium (UMEC) and the combin-
ation of UMEC with the LABA vilanterol (UMEC/VI)
are approved maintenance treatments for COPD in the
US and EU. They are not indicated for the treatment of
asthma. Previous studies have shown that both UMEC
and VI can significantly improve lung function over
24 hours [9,10]. Studies have also demonstrated that
UMEC and VI are well tolerated over a 6-month period
[11,12], but data on longer-term exposure are lacking at
present. This study was conducted to examine the safety
and tolerability of once-daily UMEC/VI 125/25 mcg and
UMEC 125 mcg compared with placebo over 12 months
in patients with COPD.
Methods
Study design
This was a Phase IIIa, multicenter, randomized, double-
blind, placebo-controlled, parallel-group study (GSK
study number DB2113359; ClinicalTrials.gov identifier
NCT01316887) conducted between January 2011 and
July 2012. Patients who met eligibility criteria entered a
run-in period of 7–10 days, followed by a 52-week treat-
ment period. Patients who experienced a COPDexacerbation or lower respiratory tract infection (LRTI)
during the run-in period or at Visit 2 were allowed to
re-screen and repeat the run-in period.
The study was conducted in accordance with the
International Conference on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals
for Human Use Good Clinical Practice (ICH) guidelines,
all applicable subject privacy requirements, and the eth-
ical principles outlined in the Declaration of Helsinki,
2008 [13,14].
Patients
Eligible patients were current or former smokers of
≥40 years of age, with a smoking history of ≥10 pack-years
and an established clinical history of COPD as defined by
the American Thoracic Society/European Respiratory
Society criteria [1]. Patients had a post-salbutamol
forced expiratory volume in one second (FEV1)/forced
vital capacity (FVC) ratio <0.70 and a post-salbutamol
FEV1 ≥35% and ≤80% of predicted values (as deter-
mined by Nutrition Health and Examination Survey III
reference equations) [15]. Female patients were eligible
for participation if they were of non-childbearing po-
tential, or agreed to practice acceptable methods of
birth control, as defined by the protocol.
Patients with a current diagnosis of asthma or other
respiratory disorder (including pulmonary hypertension
and interstitial lung disease) were excluded, as were
patients with historical/current evidence of clinically
significant, uncontrolled, cardiovascular, neurological,
psychiatric, renal, hepatic, immunological, endocrine, or
hematological abnormalities that the investigator felt
may have put the patient at risk or affected the safety
analysis of the study. Patients were also excluded if they:
had been hospitalized for COPD/pneumonia within
12 weeks prior to Visit 1 or had undergone lung resec-
tion in the 12 months prior to screening; were hyper-
sensitive to any anticholinergic drug or β2-agonist; were
unable to withhold salbutamol and/or ipratropium
bromide use for the 4-hour period prior to spirometry;
had a known or suspected history of alcohol or drug
abuse; were participating in the acute phase of a pul-
monary rehabilitation program; or had abnormal and
significant findings from electrocardiogram (ECG)
monitoring, 24-hour Holter monitoring, chest X-rays,
clinical chemistry, or hematology tests. Prohibited
medications prior to study entry are summarized in
Additional file 1: Table S1.
Study treatments and randomization
Patients were randomized in a 2:2:1 ratio to once-daily
UMEC/VI 125/25 mcg (delivering 113/22 mcg), UMEC
125 mcg (delivering 113 mcg), and placebo (Figure 1),
using a telephone-based randomization system and codes
All patients enrolled
N=893
Screen or run-in
failuresa
N=331
Randomized
N=563
Intent-to-treat
N=562
Placebo
n=109
Completed  n=66
Withdrew    n=43
UMEC 125 mcg
n=227
Completed  n=133
Withdrew    n=94
UMEC/VI 125/25 mcg
n=226
Completed  n=143
Withdrew    n=83
Figure 1 Study design. aOne patient was randomized in error but
did not receive study drug. UMEC, umeclidinium; VI, vilanterol.
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ministered in the morning via the ELLIPTA™ dry powder
inhaler. Salbutamol and/or ipratropium bromide were per-
mitted as rescue medication throughout the run-in and
treatment periods, administered via metered dose inhaler
or nebules.
Outcomes and assessments
Safety assessments included the incidence of adverse events
(AEs), vital signs and clinical chemistry, hematology, 12-
lead ECG, and 24-hour Holter ECG parameters. AE groups
of special interest, such as those associated with LAMA
and LABA pharmacologic classes, were also assessed. These
included: cardiovascular effects, effects on glucose and
potassium, tremor, urinary retention, ocular effects, gall-
bladder disorders, intestinal obstruction, and anticholiner-
gic effects. Pneumonia and LRTI were also assessed as AEs
of special interest as these are common in the COPD pa-
tient population. Additional symptomatic endpoints in-
cluded COPD exacerbations (incidence and time to first
COPD exacerbation) and rescue medication use. Lung
function endpoints included trough FEV1 and trough FVC.
For patients who did not need to re-screen as a result
of a COPD exacerbation or LRTI during the run-in
period (as outlined in the study design), there were
a total of 7 study visits at: screening (Visit 1),
randomization (Visit 2) and 1, 3, 6, 9, and 12 months
(Visits 3–7). A follow-up assessment via telephone was
conducted approximately 1 week after Visit 7, or follow-
ing withdrawal. No subsequent active follow-up was
performed. Spirometry assessments were conducted atVisit 1 (pre- and post-salbutamol) and pre-dose at Visits
2–7 to obtain FEV1 and FVC. ECGs and vital signs were
assessed prior to salbutamol dosing for spirometry
(Visit 1), and for Visits 2–7 immediately prior to dosing
and at 10 and 45 minutes post dose. Holter ECG moni-
toring and the collection of clinical laboratory samples
were conducted at Visit 1 and Visits 4–7.
Sample size and statistical analyses
The sample size was determined based on ICH guide-
lines and practical considerations. To ensure that ≥300
patients completed the study (≥120 subjects per active
treatment arm and ≥60 patients in the placebo arm), as-
suming a maximum withdrawal rate of 40% during the
52-week treatment period [16-20], it was planned that
500 patients would be randomized from approximately
50 study centers. The primary study population for all
data presentation and analyses was the intent-to-treat
(ITT) population, defined as all patients randomized to
treatment who received at least one dose of study drug.
Formal statistical analyses were performed for vital
signs and ECG parameters (analysis of covariance), time
to first COPD exacerbation (Kaplan–Meier analysis, Cox
proportional hazards model), trough FEV1 and trough
FVC (repeated measures models). No formal statistical
analyses were performed for other safety parameters or
for comparison of active treatments with placebo. Re-
sults are presented as differences and confidence inter-
vals (CIs). All other data are presented as patient
numbers and percentages by study treatment group.
Results
Patients
Of the 563 patients randomized to treatment, one did not
receive treatment and so 562 were included in the ITT
population across 53 centers in the US (28% of patients),
Romania (26%), Russian Federation (21%), South Africa
(14%), Chile (7%), and Slovakia (4%). Of these, 342 pa-
tients completed the study (UMEC/VI 125/25 mcg, 63%;
UMEC 125 mcg, 59%; placebo, 61%). Reasons for discon-
tinuation included the meeting of protocol-defined stop-
ping criteria (14%), AEs (9%), withdrawal of patient
consent (7%), lack of efficacy (2%), protocol deviation
(2%), study close/termination (2%), and loss to follow-up
(2%). Although similar overall withdrawal rates were
reported between UMEC/VI 125/25 mcg (37%), UMEC
125 mcg (41%), and placebo (39%), higher incidences of
withdrawals due to protocol-defined stopping criteria were
reported with UMEC/VI 125/25 mcg and UMEC 125 mcg
(16% in each) compared with placebo (7%), particularly
for ECG abnormalities (5–6% vs 0%) and Holter abnor-
malities (11–12% vs 7%). However, fewer patients were
withdrawn due to a lack of efficacy on active treatments
compared with placebo (≤1% vs 8%). For patients who
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primary reason for withdrawal, the ECG and Holter ab-
normalities meeting the withdrawal criteria are presented
in Additional file 1: Tables S2 and S3; no single ECG or
Holter abnormality was predominant.
Patient demographics, characteristics, and comorbid
conditions were similar across treatment groups. Overall,
patients had moderate-to-severe airflow obstruction, ex-
tensive smoking histories, and the majority were White
and male (Table 1).
Most patients had concurrent medical conditions in
addition to COPD; the most commonly reported condi-
tions were cardiovascular risk factors (67%; defined as a
current medical history of angina, myocardial infarction,
stroke, diabetes, hypertension, or hyperlipidemia) and
cardiac disorders (34%) (Table 1).
In the 12 months prior to screening, 31% of patients
in both active treatment groups and 36% of patients in
the placebo group reported at least one COPD exacerba-
tion that required oral/systemic corticosteroids and/or
antibiotics. The proportion of patients who reported at least
two of these exacerbations during this period was 11%,
14%, and 16% for UMEC 125 mcg, UMEC/VI 125/25 mcg,
and placebo groups, respectively. For exacerbations that
required hospitalization, 14%, 16%, and 17% of patients
in the UMEC 125 mcg, UMEC/VI 125/25 mcg, and
placebo groups reported at least one exacerbation, and
3%, 3%, and 6% reported at least two exacerbations.
Outcomes
AEs
The incidence of on-treatment AEs, serious AEs (SAEs)
and drug-related AEs was similar across active treatment
groups and placebo (AEs: 52–58%; SAEs: 6–7%; drug-
related AEs: 12–13%; Figures 2 and 3). On-treatment
and post-treatment fatal AEs occurred at a low incidence
across treatment groups (≤1%).
Headache was the most common AE across all treat-
ments (8–11%; Figure 3), followed by nasopharyngitis
(5–9%) and ventricular extrasystoles (5% in each treat-
ment group). In the UMEC/VI 125/25 mcg group, the
incidence of the most common AEs (reported by ≥4% of
patients) was similar to (≤1% difference) or less than pla-
cebo (Figure 3). In contrast, patients in the UMEC 125 mcg
group reported incidences of headache and nasopharyngi-
tis, ≥2% higher than placebo. AEs leading to permanent dis-
continuation or withdrawal were reported for 8% and 9% of
patients in the UMEC/VI 125/25 mcg and UMEC 125 mcg
groups, respectively, compared with 12% for placebo.
The only on-treatment SAEs reported by ≥1% of pa-
tients in any treatment group (active or placebo) were
COPD and pneumonia (all incidences ≤3%; Figure 3).
Post-treatment and drug-related SAEs had a low inci-
dence rate across treatment groups (≤1%).In the pneumonia special interest group, a higher overall
incidence of AEs was reported with UMEC 125 mcg (5%)
compared with UMEC 125/25 mcg or placebo (both 2%)
(Table 2). Patients receiving UMEC 125 mcg reported
pneumonia (3%; half of whom had received ICS before
screening and continued ICS treatment during the
study), LRTI (1%), bronchitis (<1%), bronchitis viral (<1%),
and pneumonitis (<1%); patients receiving UMEC/VI
125/25 mcg reported bronchitis, bronchitis viral, lobar
pneumonia, LRTI, and sinobronchitis (all <1%); and pa-
tients receiving placebo reported bronchitis (2%) and
tracheitis (<1%).
In the glucose effect special interest group, a higher
overall incidence of AEs was reported with UMEC/VI
125/25 mcg (4%) than UMEC 125 mcg (<1%) or placebo
(0%) (Table 2). Two patients (<1%) in the UMEC/VI
125/25 mcg group who reported hyperglycemia also re-
corded diabetes mellitus as a current medical condi-
tion at screening. Overall, patients receiving UMEC/VI
125/25 mcg reported diabetes mellitus (1%), abnormal
blood glucose (<1%), hyperglycemia (<1%), obesity (<1%),
and weight decrease (<1%). Patients receiving UMEC
125 mcg reported hyperglycemia (<1%).
In the cardiovascular special interest group, a lower over-
all incidence of AEs was reported with UMEC 125/25 mcg
(15%) than UMEC 125 mcg (22%) or placebo (23%; Table 2).
The incidence of some individual cardiovascular events was
≥2% greater with UMEC 125 mcg than placebo: sinus
tachycardia (UMEC 125 mcg, 3%; placebo, <1%); supraven-
tricular extrasystoles (UMEC 125 mcg, 3%; placebo, <1%);
supraventricular tachycardia (UMEC 125 mcg, 3%; placebo,
<1%); and rhythm idioventricular (UMEC 125 mcg, 2%;
placebo, 0%). Patients receiving UMEC/VI 125/25 mcg
reported similar or lower incidences of these events (all
<1%) than placebo.
No events were reported for any treatment in the spe-
cial interest groups relating to tremor, urinary retention,
or intestinal obstruction. Ocular effects and anticholiner-
gic syndrome were reported in <1% and 2% of patients
in each treatment group. Effects on potassium and gall-
bladder disorders were reported in <1% of patients in
the UMEC 125 mcg treatment group, but in no patients
receiving UMEC/VI 125/25 mcg or placebo (Table 2).
Overall, no individual on-treatment AE in any of the
special interest groups was reported by >5% of patients
and incidences were generally similar across treatment
groups.
Mortality
Five deaths occurred during the study: 4 (2%) in the
UMEC 125 mcg group (spine metastases, liver metasta-
ses, pneumonia, and cardiac failure) and 1 (<1%) in the
placebo group (coronary artery insufficiency). No deaths
occurred in the UMEC/VI 125/25 group. None of the
Table 1 Baseline demographics, characteristics and comorbid conditions
UMEC/VI UMEC Placebo Total
125/25 mcg 125 mcg
(n = 226)* (n = 227)* (n = 109)* (n = 562)*
Age, years
Mean (SD) 61.4 (9.01) 61.7 (9.10) 60.1 (8.28) 61.3 (8.92)
Sex, n (%)
Female 70 (31) 82 (36) 36 (33) 188 (33)
Male 156 (69) 145 (64) 73 (67) 374 (67)
Ethnicity, n (%)
Hispanic/Latino 19 (8) 17 (7) 7 (6) 43 (8)
Not Hispanic/Latino 207 (92) 210 (93) 102 (94) 519 (92)
Body mass index, kg/m2
Mean (SD) 27.89 (5.859) 28.05 (5.881) 27.65 (5.885) 27.91 (5.864)
Smoking pack-years∞
Mean (SD) 43.7 (27.49) 39.2 (21.24) 42.8 (24.71) 41.7 (24.63)
Pre-bronchodilator FEV1 (L) n = 225 n = 225 n = 108 n = 558
Mean (SD) 1.498 (0.5255) 1.432 (0.5120) 1.579 (0.5714) 1.487 (0.5311)
Post-salbutamol% predicted FEV1 (L) n = 224 n = 225 n = 109 n = 558
Mean (SD) 55.0 (12.10) 54.2 (11.81) 55.1 (11.68) 54.7 (11.89)
Reversibility to salbutamol, % n = 223 n = 224 n = 108 n = 555
Mean (SD) 12.7 (14.83) 14.2 (18.32) 11.9 (14.89) 13.1 (16.33)
GOLD Stage, n (%) n = 224 n = 225 n = 109 n = 558
I (≥80% predicted FEV1) 0 0 1 (<1) 1 (<1)
II (≥50– <80% predicted FEV1) 137 (61) 129 (57) 71 (65) 337 (60)
III (≥30– <50% predicted FEV1) 87 (39) 96 (43) 37 (34) 220 (39)
IV (<30% predicted FEV1) 0 0 0 0
Reversible to salbutamol, n (%)† n = 223 n = 224 n = 108 n = 555
Reversible 78 (35) 72 (32) 36 (33) 186 (34)
Non-reversible 145 (65) 152 (68) 72 (67) 369 (66)
ICS use, n (%)‡
ICS users 80 (35) 73 (32) 40 (37) 193 (34)
ICS non-users 146 (65) 154 (68) 69 (63) 369 (66)
Current medical conditions, n (%)
Any condition 190 (84) 196 (86) 88 (81) 474 (84)
Cardiovascular risk factors§ 151 (67) 155 (68) 70 (64) 376 (67)
Cardiac disorders 74 (33) 80 (35) 37 (34) 191 (34)
Musculoskeletal and connective tissue disorders 84 (37) 64 (28) 32 (29) 180 (32)
Metabolism and nutrition disorders 35 (15) 35 (15) 18 (17) 88 (16)
Psychiatric disorders 33 (15) 36 (16) 15 (14) 84 (15)
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Table 1 Baseline demographics, characteristics and comorbid conditions (Continued)
Vascular disorders 26 (12) 26 (11) 15 (14) 67 (12)
Endocrine disorders 26 (12) 15 (7) 13 (12) 54 (10)
Nervous system disorders 19 (8) 19 (8) 11 (10) 49 (9)
*Unless otherwise specified; ∞Smoking pack-years = (number of cigarettes smoked per day/20) x number of years smoked prior to screening; †reversible was an
increase in FEV1 ≥12% and ≥200 mL following administration of salbutamol; non-reversible was an increase in FEV1 of <200 mL or a ≥200 mL increase that was
<12% from pre-salbutamol FEV1;
‡ICS use was defined as those patients who were currently taking ICS medications at the Screening Visit; §cardiovascular risk
factors defined as current medical history of angina, myocardial infarction, stroke, diabetes, hypertension, or hyperlipidemia.
FEV1, forced expiratory volume in one second; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; SD, standard deviation;
UMEC, umeclidinium; VI, vilanterol.
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by the reporting investigator.Clinical laboratory evaluations and vital signs
There was no clinically significant change from baseline
in any clinical chemistry or hematology parameter in
any treatment group, including glucose levels. Similarly,
there was no evidence of a treatment-related effect on
vital signs (systolic blood pressure, diastolic blood pres-
sure, or pulse rate).ECG parameters
The proportions of patients with one or more abnormal,
clinically significant 12-lead ECG interpretation at any
time post-baseline was similar across all treatment groups
(23–26%). Post-baseline ECG abnormalities that occurred
with an incidence ≥2% higher than placebo were frequent
ventricular depolarization (UMEC/VI 125/25 mcg, 5%;
UMEC 125 mcg, 6%; placebo, <1%), ectopic supraventric-
ular beats (UMEC/VI 125/25 mcg, 3%; UMEC 125 mcg
4%; placebo, <1%), right bundle branch block (UMEC
125/25 mcg, 4%; UMEC 125 mcg, 3%; placebo, 2%), and
first degree atrioventricular block (UMEC 125/25 mcg,
2%; UMEC 125 mcg, 3%; placebo <1%).0
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The mean changes from baseline in heart rate were
generally small in all treatment groups at all visits, with
no evidence of a treatment-related effect. No clinically
relevant treatment differences in QTc interval, PR inter-
val, or heart rate were observed between treatment
groups at any time point.
Trough FEV1 and FVC
Greater mean changes from baseline in trough FEV1 and
FVC were demonstrated for UMEC/VI 125/25 mcg and
UMEC 125 mcg compared with placebo at all visits
(Figure 4). At 12 months, UMEC/VI 125/25 mcg and
UMEC 125 mcg had improved trough FEV1 in comparison
with placebo by 0.231 L (95% CI: 0.153, 0.310) and 0.178 L
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0.312), respectively.
COPD exacerbations and rescue use
There were fewer patients reporting COPD exacerba-
tions with UMEC/VI 125/25 mcg and UMEC 125 mcg
(13% and 15%) compared with placebo (24%). COPD
exacerbations resulting in hospitalization were also
fewer with both UMEC/VI 125/25 mcg (6%) and UMEC
125 mcg (7%) compared with placebo (12%). Furthermore,
based on analysis of time to first exacerbation, both
UMEC/VI 125/25 mcg and UMEC 125 mcg were associ-
ated with a lower risk of COPD exacerbation compared
with placebo (hazard ratio [HR] = 0.6, 95% CI: 0.3, 1.0, risk
reduction 40%; HR = 0.4, 95% CI: 0.3, 0.8, risk reductionTable 2 Summary of on-treatment AEs of special interest
Special interest
AE group
Number (%) of patients
UMEC/VI UMEC Placebo
125/25 mcg 125 mcg
(n = 226) (n = 227) (n = 109)
Cardiovascular 34 (15) 49 (22) 25 (23)
Pneumonia 5 (2) 11 (5) 2 (2)
Anticholinergic syndrome 5 (2) 5 (2) 2 (2)
Effects on glucose 8 (4) 1 (<1) 0
Ocular effects 1 (<1) 1 (<1) 1 (<1)
Gallbladder disorders 0 2 (<1) 0
Effects on potassium 0 1 (<1) 0
Tremor 0 0 0
Urinary retention 0 0 0
Intestinal obstruction 0 0 0
AE, adverse event; UMEC, umeclidinium; VI, vilanterol.60%, respectively) (Figure 5). On average, less rescue medi-
cation was required with UMEC/VI 125/25 mcg and
UMEC 125 mcg (1.6 and 2.2 puffs/day) compared with
placebo (2.6 puffs/day), while the mean change from
baseline in the percentage of rescue-free days was
greater with UMEC/VI 125/25 mcg (23%) than UMEC
125 mcg (13%) or placebo (11%).
Discussion
This study aimed to examine the safety and tolerability
of UMEC/VI 125/25 mcg and UMEC 125 mcg com-
pared with placebo when administered over 12 months
in patients with COPD. The population enrolled showed
similar characteristics to the general COPD population
and to that of previous clinical studies evaluating long-
acting bronchodilators for the maintenance treatment of
COPD [21-23]. The majority of patients had a history of
cardiovascular risk factors (64–68%) at baseline, but the
incidence was balanced across treatment groups. Overall,
UMEC/VI 125/25 mcg and UMEC 125 mcg were well
tolerated for up to 12 months, with no clinically mean-
ingful treatment-related changes in vital signs or clinical
laboratory parameters. No additive effects on AEs or
safety assessments were noted with UMEC/VI 125/25 mcg
compared with UMEC monotherapy, which is consistent
with previous UMEC/VI studies [11,12,24].
Both AE and ECG data suggested that UMEC 125 mcg
may be associated with an increase in atrial arrhythmias.
However, the observations of supraventricular tachycardia
and supraventricular extrasystoles were not associated
with reports of clinically relevant symptoms such as
hypotension or syncope, suggesting these arrhythmias
may not be clinically meaningful. Nevertheless, data from
other clinical trials suggests that atrial arrhythmias may be
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Figure 4 LS mean change from baseline in trough FEV1 (A) and FVC (B). CI, confidence interval; FEV1, forced expiratory volume in one
second; FVC, forced vital capacity; LS, least squares; UMEC, umeclidinium; VI, vilanterol.
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http://respiratory-research.com/content/15/1/78a class effect associated with anticholinergics [25]. Results
from the Lung Health Study showed an increased risk of
supraventricular tachycardia with the short-acting anti-
cholinergic ipratropium bromide [26]. In the Understand-
ing the Long-Term Impact of Tiotropium on Lung
Function Trial (UPLIFT), there was an increased relative
risk of tachyarrhythmias and atrial tachycardias reported
as AEs for tiotropium compared with placebo [27], and inTime to event (days)
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Figure 5 Time to first COPD exacerbation. COPD, chronic
obstructive pulmonary disease; UMEC, umeclidinium; VI, vilanterol.the tiotropium active comparator studies performed in the
UMEC and UMEC/VI development program there were
also some increases in atrial arrhythmias compared with
baseline. A recently approved LAMA, aclidinium, has also
been shown to have a greater incidence of non-sustained
supraventricular tachycardias compared with placebo [28].
Interestingly, in this study the incidence of atrial arrhyth-
mias with UMEC/VI 125/25 mcg was generally similar to
placebo.
Although there were no formal efficacy endpoints in the
present study, greater improvements from baseline in lung
function were observed with both UMEC/VI 125/25 mcg
and UMEC 125 mcg compared with placebo, together
with reductions in COPD exacerbations and rescue
medication use. These improvements were sustained over
12 months, indicating no tolerance issues and supporting
findings from recent randomized controlled trials [11,12].
However, the present study was neither designed nor pow-
ered to detect differences in lung function outcomes or
COPD exacerbations, and as such statistical conclusions
cannot be drawn on the relative efficacy of the treatments.
Conclusions
Overall, UMEC/VI 125/25 mcg and UMEC 125 mcg
were well tolerated over 12 months of treatment in pa-
tients with COPD, and provided greater improvements
Donohue et al. Respiratory Research 2014, 15:78 Page 9 of 10
http://respiratory-research.com/content/15/1/78from baseline in lung function and rescue medication
use than placebo. These findings are supportive of the
use of UMEC/VI and UMEC for the long-term treat-
ment of COPD.
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